Skip to main content
ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
6.96
-0.33 (-4.53%)
At close: Apr 28, 2026, 4:00 PM EDT
6.98
+0.02 (0.29%)
After-hours: Apr 28, 2026, 7:59 PM EDT

ImmunityBio Revenue

In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth. ImmunityBio had revenue of $38.29M in the quarter ending December 31, 2025, with 406.95% growth.

Revenue (ttm)
$113.29M
Revenue Growth
+668.31%
P/S Ratio
63.45
Revenue / Employee
$163,948
Employees
691
Market Cap
7.19B

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025113.29M98.54M668.31%
Dec 31, 202414.75M14.12M2,270.58%
Dec 31, 2023622.00K382.00K159.17%
Dec 31, 2022240.00K-694.00K-74.30%
Dec 31, 2021934.00K329.00K54.38%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Halozyme Therapeutics 1.40B
Bio-Techne 1.22B
Krystal Biotech 389.13M
Cytokinetics 88.04M
Protagonist Therapeutics 46.02M
Kymera Therapeutics 39.21M
Arcellx 22.29M
Revenue Rankings

IBRX News

More News